The Meb Faber Show - Better Investing Dan Rasmussen & D.A. Wallach on The Future of Biotech and Healthcare | #589
15 snips
Jul 4, 2025 
In this episode, Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture investor and musician, dive into the exciting world of biotech and healthcare. They discuss the transformative impact of AI and emerging treatments like gene therapy on patient care. The duo shares insights on private equity dynamics and investment strategies, especially in the context of rising interest rates. They also touch on global market trends and Japan's corporate reforms, highlighting unique investment opportunities in the evolving landscape.
AI Snips
Chapters
Transcript
Episode notes
Why Biotech Collapsed
- Biotech's valuation collapse is mainly due to increased interest rates raising discount rates on future cash flows.
- Public investor rotation away and IPO market shutdown severely limited capital for biotech companies.
Biotech’s Unique Investment Characteristics
- Biotech is unique, with many companies losing money long-term but a small minority producing outsized returns.
- Traditional financial models misclassify biotech firms due to their negative earnings and cash burn dynamics.
Innovation Cuts Healthcare Costs
- Pharmaceutical innovation like mRNA vaccines is the most cost-effective way to reduce downstream healthcare costs.
- AI will democratize access to top-tier medical knowledge, potentially solving system inefficiencies.